

Divestiture of MatrixCare Business

Investor Relations
July 2026

Presentation of Financial Information & Forward-Looking Statements

Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities for the periods indicated.

This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Gross Profit, non-GAAP Gross Margin, non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.Resmed.com).

In addition to historical information, this presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed’s current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, and tax outlook. The words “believe,” “expect,” “intend,” “anticipate,” “will continue,” “will,” “estimate,” “plan,” “future” and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions on our business.

We have not included a reconciliation for forward-looking non-GAAP financial measures where we are unable to provide a meaningful or accurate calculation or estimation of reconciling items, and the information is not available without unreasonable effort. This is due to the inherent difficulty of forecasting the occurrence and the financial impact of various items that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, we are unable to address the probable significance of the unavailable information. Forward-looking non-GAAP financial measures provided without the most directly comparable GAAP financial measures may vary materially from the corresponding GAAP financial measures.

ResMed’s expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the “Risk Factors” identified in ResMed’s quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements.

Transaction Overview



Divestiture of

MatrixCare[®]

Business¹

Signed June 30, 2026
Expected close Q1 FY27

1

Divestiture of MatrixCare Business¹ within Resmed's Residential Care Software (RCS) segment.

2

Robust process resulting in Frazier Healthcare Partners as acquiror.

3

Portfolio optimization to sharpen focus on core growth areas: sleep, breathing, and connected home-based care.

4

Expected close is during Resmed's Q1 FY27. Until closing, MatrixCare Business¹ will continue to operate as part of Resmed. Transition service agreements (TSAs) in place.

5

All-cash transaction. Uses of proceeds include return of cash to shareholders and general corporate purposes.

Residential Care Software: Looking Forward

- Post-transaction close, Residential Care Software (RCS) will be comprised of **Brightree & MEDIFOX DAN**
- Expect RCS to **accelerate to HSD revenue growth, with operating leverage, in FY27**
- Sharpened **focus on core** in sleep, breathing, and connected home-based care
- Continue to **reallocate capital** toward higher-growth, higher-return opportunities
- **Accelerates** digital health ecosystem expansion, supporting **continued innovation and scale**, and driving **progress toward our 2030 strategy**

Financial Modeling Considerations

Transaction Details

- **\$490 million** all-cash transaction subject to certain closing adjustments; expected to **close** during **Q1 FY27**
- Until closing, MatrixCare Business¹ will continue to operate as part of RMD

P&L Impacts

- Based on preliminary financial results for the full fiscal year 2026, the MatrixCare Business¹ represented **~\$220 million of revenue** and **~\$55 million of non-GAAP operating profit**
- RMD expects to enter into **TSAs** for a period of time **to largely offset any stranded costs in year one** post-closing, while we work to mitigate and remove any remaining stranded costs over time

Use of Proceeds

- RMD will use net proceeds to **return capital to shareholders**, including through an **accelerated share repurchase (ASR) program**, and for general corporate purposes

Additional Outlook Considerations

Noctrix

- Noctrix expected to contribute **~\$30M in revenue** and **reduce non-GAAP fully diluted EPS by ~\$0.20** in FY27

FY26

- **Reiterating full year FY26 outlook** for non-GAAP gross margin, non-GAAP SG&A as a % of revenue, R&D as a % of revenue, and non-GAAP tax rate as provided on RMD's Q3 FY26 earnings call on April 30, 2026
- **Reiterating Q4 FY26 outlook** for net interest income and planned share repurchases as provided on RMD's Q3 FY26 earnings call on April 30, 2026

FY27

- **RMD FY27 outlook** will be provided during RMD's Q4 FY26 earnings call on August 6, 2026